Seer to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Seer, Inc. (Nasdaq: SEER) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022. The management team is scheduled to present at 8:15 a.m. Pacific Time and will hold a Q&A session. A live webcast will be available on Seer's investor website, with an archived replay accessible afterward.

Seer specializes in developing products for proteomic analysis, including the Proteograph™ Product Suite, designed for deep and unbiased analysis in a streamlined manner. This product is intended for research use only.

REDWOOD CITY, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will participate in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

Seer’s management is scheduled to present and participate in a Q&A session on Monday, January 10 at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. A live webcast of the virtual session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.

About Seer

Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer is commercializing its Proteograph™ Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Investor Contact
Carrie Mendivil
investor@seer.bio

Media Contact
Karen Possemato
pr@seer.bio

FAQ

When is Seer presenting at the J.P. Morgan Healthcare Conference?

Seer's presentation at the J.P. Morgan Healthcare Conference is scheduled for January 10, 2022, at 8:15 a.m. Pacific Time.

Where can I watch Seer's presentation from the J.P. Morgan Healthcare Conference?

You can watch Seer's presentation live on their investor website, with an archived replay available afterward.

What is the Proteograph Product Suite developed by Seer?

The Proteograph Product Suite is an integrated solution for performing deep, unbiased proteomic analysis quickly and efficiently.

Is the Proteograph Product Suite intended for diagnostic use?

No, the Proteograph Product Suite is for research use only and is not intended for diagnostic procedures.

What does Seer specialize in?

Seer specializes in life sciences, specifically in developing transformative products for proteomics.